ORLANDO - In a press release on July 1, Orlando Health announced that is now “one of the first health systems in the nation” ...

TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...

Add Yahoo as a preferred source to see more of our stories on Google. Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug ...

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for prostate ...

The technology focuses ultrasound delivered through a device placed on the skin rather than through the urethra or rectum.

Transurethral ablation of Gleason grade group 2 (GG2) lesions using water vapor therapy cleared the area of prostate cancer in 75% of men and 91% had no GG2 or higher-grade cancer remaining at 6 ...

Researchers developed an approach to treating prostate cancer, successfully eliminating cancerous cells in 73% of patients in the study. Prostate cancer is the second leading cause of cancer death ...

Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated, or they’re serious enough to require surgery and radiation. Monitoring can cause patients anxiety.